Certara
| General Information | |
| Business: |
We accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development.
Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions that not only save significant time and money but also advance drug safety and efficacy, improving millions of lives each year.
(Note: The Certara deal was upsized at pricing: 29.1 million shares were priced at $23, up from 24.4 million shares at $19 to $22 in the prospectus.)
|
| Industry: | PREPACKAGED SOFTWARE |
| Employees: | 899 |
| Founded: | 2017 |
| Contact Information | |
| Address | 100 Overlook Center, Suite 101, Princeton, NJ 08540, US |
| Phone Number | (609) 716-7900 |
| Web Address | http://www.certara.com |
| View Prospectus: | Certara |
| Financial Information | |
| Market Cap | |
| Revenues | $232.7 mil (last 12 months) |
| Net Income | $1.99 mil (last 12 months) |
| IPO Profile | |
| Symbol | CERT |
| Exchange | NASDAQ |
| Shares (millions): | 29.1 |
| Price range | $23.00 - $23.00 |
| Est. $ Volume | $669.3 mil |
| Manager / Joint Managers | Jefferies/ Morgan Stanley/ BofA Securities/ Credit Suisse/ Barclays/ William Blair |
| CO-Managers | - |
| Expected To Trade: | 12/11/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |